Liver resection

肝切除术
  • 文章类型: Journal Article
    淋巴结状态是肝内胆管癌(ICC)的重要预后因素。然而,临床淋巴结阴性ICC患者进行淋巴结清扫(LND)的预后价值仍存在争议.这项研究的目的是评估LND对该亚组患者长期结局的临床价值。
    我们回顾性分析了来自三个三级肝胆中心的因临床淋巴结阴性ICC而接受根治性肝切除术的患者。在有和没有LND的患者之间进行基于临床病理数据的1:1比例的倾向评分匹配分析。在匹配的队列中比较了无复发生存率(RFS)和总生存率(OS)。
    在303例接受根治性肝切除术的患者中,48例临床阳性淋巴结患者被排除在外,共有159名临床淋巴结阴性的ICC患者最终符合研究条件,LND组102名,非LND组57名。在倾向得分匹配后,我们对两组均衡的51例患者进行了分析.中位数RFS无显著差异(12.0vs.10.0个月,P=0.37)和中位OS(22.0与26.0个月,在LND组和非LND组之间观察到P=0.47)。此外,LND未被确定为生存的独立风险之一。在接受LND的51名患者中,11例患者淋巴结阳性(淋巴结转移(LNM)()),结果明显比LND(-)差。另一方面,术后辅助治疗是RFS(风险比(HR):0.623,95%置信区间(CI):0.393~0.987,P=0.044)和OS(HR:0.585,95%CI:0.359~0.952,P=0.031)的独立危险因素.此外,术后辅助治疗与非LND患者的生存期延长相关(RFSP=0.02,OSP=0.03).
    根据数据,我们发现LND并不能显著改善临床淋巴结阴性ICC患者的预后.术后辅助治疗与ICC患者生存期延长相关,特别是在非LND个人中。
    UNASSIGNED: Lymph node status is a prominent prognostic factor for intrahepatic cholangiocarcinoma (ICC). However, the prognostic value of performing lymph node dissection (LND) in patients with clinical node-negative ICC remains controversial. The aim of this study was to evaluate the clinical value of LND on long-term outcomes in this subgroup of patients.
    UNASSIGNED: We retrospectively analyzed patients who underwent radical liver resection for clinically node-negative ICC from three tertiary hepatobiliary centers. The propensity score matching analysis at 1:1 ratio based on clinicopathological data was conducted between patients with and without LND. Recurrence-free survival (RFS) and overall survival (OS) were compared in the matched cohort.
    UNASSIGNED: Among 303 patients who underwent radical liver resection for ICC, 48 patients with clinically positive nodes were excluded, and a total of 159 clinically node-negative ICC patients were finally eligible for the study, with 102 in the LND group and 57 in the non-LND group. After propensity score matching, two well-balanced groups of 51 patients each were analyzed. No significant difference of median RFS (12.0 vs. 10.0 months, P = 0.37) and median OS (22.0 vs. 26.0 months, P = 0.47) was observed between the LND and non-LND group. Also, LND was not identified as one of the independent risks for survival. Among 51 patients who received LND, 11 patients were with positive lymph nodes (lymph node metastasis (LNM) (+)) and presented significantly worse outcomes than those with LND (-). On the other hand, postoperative adjuvant therapy was the independent risk factor for both RFS (hazard ratio (HR): 0.623, 95% confidence interval (CI): 0.393 - 0.987, P = 0.044) and OS (HR: 0.585, 95% CI: 0.359 - 0.952, P = 0.031). Furthermore, postoperative adjuvant therapy was associated with prolonged survivals of non-LND patients (P = 0.02 for RFS and P = 0.03 for OS).
    UNASSIGNED: Based on the data, we found that LND did not significantly improve the prognosis of patients with clinically node-negative ICC. Postoperative adjuvant therapy was associated with prolonged survival of ICC patients, especially in non-LND individuals.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:确定罗哌卡因单次注射双侧后方肌阻滞(QLB)是否可以改善腹腔镜肝切除术后最初24h的术后镇痛效果。与0.9%盐水相比。
    方法:前瞻性,双盲,随机对照试验。
    方法:从2021年11月到2023年1月建立一个单一的三级护理中心。
    方法:共有94例因肝细胞癌而计划进行腹腔镜肝切除术的患者。
    方法:将94例患者随机分为QLB组(每侧接受20mL0.375%罗哌卡因,总共150毫克)或对照组(每侧接受20毫升0.9%盐水)。
    方法:主要结果是术后最初24小时内的累积阿片类药物消耗量。次要结果包括疼痛评分和术中和恢复参数。
    结果:QLB组(n=46)术后24小时的平均累积阿片类药物消耗量为30.8±22.4mg,对照组为34.0±19.4mg(n=46,平均差异:-3.3mg,95%置信区间,-11.9至5.4,p=0.457)。QLB组术后1h的平均静息疼痛评分明显低于对照组(5[4-6.25]vs.7[4.75-8],p=0.035)。在其他时间点或其他次要结局中,静息或咳嗽疼痛评分未观察到显着的组间差异。
    结论:术前双侧后QLB没有减少腹腔镜肝切除术后最初24小时内的累积阿片类药物消耗量。
    OBJECTIVE: To determine if single-injection bilateral posterior quadratus lumborum block (QLB) with ropivacaine would improve postoperative analgesia in the first 24 h after laparoscopic hepatectomy, compared with 0.9% saline.
    METHODS: Prospective, double blinded, randomized controlled trial.
    METHODS: A single tertiary care center from November 2021 and January 2023.
    METHODS: A total of 94 patients scheduled to undergo laparoscopic hepatectomy due to hepatocellular carcinoma.
    METHODS: Ninety-four patients were randomized into a QLB group (receiving 20 mL of 0.375% ropivacaine on each side, 150 mg in total) or a control group (receiving 20 mL of 0.9% saline on each side).
    METHODS: The primary outcome was the cumulative opioid consumption during the initial 24-h post-surgery. Secondary outcomes included pain scores and intraoperative and recovery parameters.
    RESULTS: The mean cumulative opioid consumption during the initial 24-h post-surgery was 30.8 ± 22.4 mg in the QLB group (n = 46) and 34.0 ± 19.4 mg in the control group (n = 46, mean differences: -3.3 mg, 95% confidence interval, -11.9 to 5.4, p = 0.457). The mean resting pain score at 1 h post-surgery was significantly lower in the QLB group than in the control group (5 [4-6.25] vs. 7 [4.75-8], p = 0.035). No significant intergroup differences were observed in the resting or coughing pain scores at other time points or in other secondary outcomes.
    CONCLUSIONS: Preoperative bilateral posterior QLB did not reduce cumulative opioid consumption during the first 24 h after laparoscopic hepatectomy.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    肝切除术后肝功能衰竭(PHLF)仍然是肝切除术后死亡的主要原因。氧化应激与术后并发症有关,但其对肝功能的影响尚不清楚。这是第一个在人类中,prospective,单中心,观察性试验研究根据ISGLS(国际肝脏外科研究小组)评估围手术期氧化应激和PHLF。血清8-异前列腺素,4-羟基壬烯醛(4-HNE),总抗氧化能力,维生素A和E,术中,顺序肝组织4-HNE和UCP2(解偶联蛋白2)免疫组织化学(IHC)进行评估。分析了与已知PHLF危险因素的相互作用以及氧化应激标志物的预测潜力。总的来说,包括52例患者(69.2%的主要肝切除)。13例患者(25%)经历过PHLF,90天死亡率的主要因素(23%vs.0%;p=0.013)。切除后,促氧化8-异前列腺素显著增加(p=0.038),而4-HNE立即下降(p<0.001)。抗氧化标记物显示切除术后开始的消耗模式(p<0.001)。从剖腹手术后的活检到切除后的原位肝和切除标本,肝组织氧化应激逐步增加(所有p<0.001)。胆管癌患者在不同时间点表现出显著较高的血清和组织氧化应激水平,在晚期肿瘤阶段,术前值始终较高。结合术中,切除后4-HNE血清水平和原位IHC早期预测的PHLF,AUC为0.855(63.6%vs.0%;p<0.001)。这也与B/C级PHLF(36.4%与0%;p=0.021)和90天死亡率(18.2%vs.0%;p=0.036)。总之,肝功能障碍患者围手术期氧化应激水平的不同模式.结合术中血清和肝组织标志物可预测随后的PHLF。胆管癌患者表现出明显的全身和肝脏氧化应激,随着肿瘤晚期水平的增加,因此代表了未来探索性和治疗性研究的一个有价值的目标.
    Post-hepatectomy liver failure (PHLF) remains the major contributor to death after liver resection. Oxidative stress is associated with postoperative complications, but its impact on liver function is unclear. This first in-human, prospective, single-center, observational pilot study evaluated perioperative oxidative stress and PHLF according to the ISGLS (International Study Group for Liver Surgery). Serum 8-isoprostane, 4-hydroxynonenal (4-HNE), total antioxidative capacity, vitamins A and E, and intraoperative, sequential hepatic tissue 4-HNE and UCP2 (uncoupling protein 2) immunohistochemistry (IHC) were assessed. The interaction with known risk factors for PHLF and the predictive potential of oxidative stress markers were analyzed. Overall, 52 patients were included (69.2% major liver resection). Thirteen patients (25%) experienced PHLF, a major factor for 90-day mortality (23% vs. 0%; p = 0.013). Post-resection, pro-oxidative 8-isoprostane significantly increased (p = 0.038), while 4-HNE declined immediately (p < 0.001). Antioxidative markers showed patterns of consumption starting post-resection (p < 0.001). Liver tissue oxidative stress increased stepwise from biopsies taken after laparotomy to post-resection in situ liver and resection specimens (all p < 0.001). Cholangiocarcinoma patients demonstrated significantly higher serum and tissue oxidative stress levels at various timepoints, with consistently higher preoperative values in advanced tumor stages. Combining intraoperative, post-resection 4-HNE serum levels and in situ IHC early predicted PHLF with an AUC of 0.855 (63.6% vs. 0%; p < 0.001). This was also associated with grade B/C PHLF (36.4% vs. 0%; p = 0.021) and 90-day mortality (18.2% vs. 0%; p = 0.036). In conclusion, distinct patterns of perioperative oxidative stress levels occur in patients with liver dysfunction. Combining intraoperative serum and liver tissue markers predicts subsequent PHLF. Cholangiocarcinoma patients demonstrated pronounced systemic and hepatic oxidative stress, with increasing levels in advanced tumor stages, thus representing a worthwhile target for future exploratory and therapeutic studies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:术中吲哚菁绿(ICG)荧光成像已被证明是一种新的创新方法,可以说明肝细胞癌肝切除术中的最佳切除边缘。这项研究通过研究ICG强度梯度与切除标本的病理检查结果的相关性,调查了其在切除边缘确定中的准确性。
    方法:这是一个前瞻性的,单中心,非随机对照研究。招募具有指示肝切除的肝肿瘤的患者。假设是,使用术中近红外/ICG荧光成像将是一个有希望的指导工具,以更好的切除边缘切除肝细胞癌。术前1天给予ICG(0.25mg/kg)。在荧光成像系统下检查切除的样本。活检取自肿瘤和正常组织。将从ICG荧光成像获得的颜色信号与活检进行比较以进行分析。
    结果:招募了22名患者进行研究。其肿瘤的中值大小为2.25cm。一名患者有切除边缘受累。在ICG荧光下,肿瘤通常呈黄色,被绿色的区域包裹着。17例患者(77.3%)肿瘤呈黄色,确诊为恶性肿瘤,而12例患者(54.5%)的肿瘤显示绿色,并被证实为恶性肿瘤。使用受试者工作特征曲线来测量绿色的敏感性和特异性,以寻找清晰的切除边缘。曲线下面积为85.3%(p=0.019,95%置信区间0.696-1.000),灵敏度为0.706,特异性为1.000。
    结论:使用ICG荧光有助于确定切除边缘。肿瘤切除应包括完全切除荧光图像中显示的绿色区域。
    BACKGROUND: Intraoperative indocyanine green (ICG) fluorescence imaging has been shown to be a new and innovative way to illustrate the optimal resection margin in hepatectomy for hepatocellular carcinoma. This study investigated its accuracy in resection margin determination by looking into the correlation of ICG intensity gradients with pathological examination results of resected specimens.
    METHODS: This was a prospective, single-center, non-randomized controlled study. Patients who had liver tumors indicating liver resection were recruited. The hypothesis was that the use of intraoperative near-infrared/ICG fluorescence imaging would be a promising guiding tool for removing hepatocellular carcinoma with a better resection margin. Patients were given ICG (0.25 mg/kg) 1 day before operation. Resected specimens were inspected under a fluorescent imaging system. Biopsies were taken from tumors and normal tissue. Color signals obtained from ICG fluorescence imaging were compared with biopsies for analysis.
    RESULTS: Twenty-two patients were recruited for study. The median size of their tumors was 2.25 cm. One patient had resection margin involvement. Under ICG fluorescence, the tumors typically lighted up as yellow color, wrapped by a zone of green color. Tumors of 17 patients (77.3%) displayed yellow color and were confirmed malignancy, while tumors of 12 patients (54.5%) displayed green color and were confirmed malignancy. Receiver operating characteristic curve was used to measure the sensitivity and specificity of the green color to look for a clear resection margin. The area under the curve was 85.3% (p = 0.019, 95% confidence interval 0.696-1.000), with a sensitivity of 0.706 and specificity of 1.000.
    CONCLUSIONS: The use of ICG fluorescence can be helpful in determining resection margins. Resection of tumor should include complete resection of the green zone shown in the fluorescence image.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:为了最大限度地发挥效用并防止过早的肝移植(LT),2015年,法国在等待期接受切除或热消融治疗的任何单个HCC患者中采用了延迟LT策略(DS),推迟LT直到复发。这项研究的目的是评估DS,以确保其不会妨碍DS患者的LT前后结局。
    方法:研究了2015年至2018年在法国列出的HCC患者。从国家LT数据库中提取数据后,2,025例患者根据6组进行了鉴定和分类:单个肿瘤进入DS,单个肿瘤未进入DS,多发性肿瘤,没有治愈性治疗,无法治疗的HCC或T1肿瘤。18个月的Kaplan-Meier估计因死亡而辍学,在LT之前病得太重,无法移植或肿瘤进展,比较5年LT后HCC复发和LT后生存率。
    结果:DS组的平均等待时间为910天。与其他组相比,DS的LT前退出概率显着降低(13%vs19%,p=0.0043),并且在T1组中明显更高(25.4%,p=0.05)。多结节组的LT术后HCC复发率明显较高(19.6%,p=0.019),LT后5年生存率在DS组为74%(p=0.22)。
    结论:DELTAHCC研究表明,DS不会对LT前后患者的预后产生负面影响,并有可能将器官重新分配给更迫切需要LT的患者。可以合理地提出和追求。T1患者意外的高辍学风险似乎与基于MELD的驾驶规则不足,呼吁修改分配规则。
    为了最大限度地发挥效用并防止过早的肝移植(LT),法国于2015年采用了延迟LT策略(DS)。它包括推迟LT,直到通过手术切除或热消融治疗的任何单个HCC患者复发。DELTAHCC研究旨在评估这一全国性策略。它显示在一个非美国,欧洲LT计划,DS:-不会对LT患者前后结局产生负面影响,-涉及多达20%的LT候选人-因此有可能将器官重新分配给更迫切需要LT的患者。可以合理地采用这种延迟策略并将其扩展到其他LT计划。值得注意的是,T1患者出现意外的高脱落风险,似乎与基于MELD的提供规则有关,这些规则对这些患者的服务不足,要求进一步审查和修订此子组中的分配规则。
    OBJECTIVE: To maximize utility and prevent premature liver transplantation (LT), a delayed LT strategy (DS) was adopted in France in 2015 in patients listed for any single HCC treated with resection or thermal ablation during the waiting phase. The DS involves postponing LT until recurrence. The purpose of this study was to evaluate the DS to make sure that it did not hamper pre- and post-LT outcomes.
    METHODS: Patients listed for HCC in France between 2015 and 2018 were studied. After data extraction from the national LT database, 2,025 patients were identified and classified according to six groups: single tumor entering DS, single tumor not entering DS, multiple tumors, no curative treatment, untreatable HCC or T1 tumors. Kaplan-Meier estimates of the 18-month risk of dropout for death, too sick to be transplanted or tumor progression before LT, 5-year post-LT HCC recurrence and post-LT survival rates were compared.
    RESULTS: Median waiting-time in the DS group was 910 days. Pre-LT dropout probability was significantly lower in the DS group compared to other groups (13% vs. 19%, p = 0.0043) and significantly higher in the T1 group (25.4%, p = 0.05). Post-LT HCC recurrence rate in the multiple nodules group was significantly higher (19.6%, p = 0.019), while 5-year post-LT survival did not differ among groups and was 74% in the DS group (p = 0.22).
    CONCLUSIONS: The DELTA-HCC study shows that DS does not negatively impact either pre- nor post-LT patient outcomes, and has the potential to allow for redistribution of organs to patients in more urgent need of LT. It can reasonably be proposed and pursued. The unexpectedly high risk of dropout in T1 patients seems related to the MELD-based offering rules underserving this subgroup.
    UNASSIGNED: To maximize utility and prevent premature liver transplantation (LT), a delayed LT strategy was adopted in France in 2015. It involves postponing LT until recurrence in patients listed for any single HCC curatively treated by surgical resection or thermal ablation. The DELTA-HCC study was conducted to evaluate this nationwide strategy. It shows in a European LT program that delayed strategy does not negatively impact pre- nor post-LT patient outcomes and is relevant to up to 20% of LT candidates; thus, it could potentially enable the redistribution of organs to patients in more urgent need of LT. Such a delayed strategy can reasonably be pursued and extended to other LT programs. Of note, an unexpectedly high risk of dropout in T1 patients, seemingly related to MELD-based offering rules which underserve these patients, calls for further scrutinization and revision of allocation rules in this subgroup.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    腹腔镜肝脏手术的发展,围手术期护理计划的改进,和手术创新已经允许肝切除选定的肝硬化患者。然而,肝脏手术的大部分ERAS研究都是在肝实质正常的患者身上进行的,而其在肝硬化患者中的应用是有限的。这项研究的目的是评估ERAS方案在接受肝脏手术的肝硬化患者中的实施。我们提出了一项分析观察性前瞻性队列研究,其中包括在2017年12月至2019年12月期间接受ERAS项目肝切除术的所有成年患者.我们比较肝硬化(CG)/非肝硬化(NCG)患者的预后。共纳入101例患者。其中30例(29.7%)为≥70例肝硬化患者。两组中87%的人进行了>70%的ERAS。两组术后第一天的口服饮食耐受性和动员相似。两组的住院时间相似(2.9天/2.99天)。发病率和死亡率相似;ClavienI-II(CG:44%vsNCG:30%)和Clavien≥III(CG:3%vsNCG:8%)。在NCG中,重新进入医院的比例更高。该研究的总死亡率为1%。在两个研究组中,ERAS方案的依从性与并发症的减少相关(ERAS<70%:80%vsERAS>90%:20%;p:0.02)和并发症严重程度的降低。ERAS计划在接受肝脏手术的肝硬化患者中的应用是可行的,安全,和可重复的。它允许术后并发症,死亡率,住院,再入院率与标准患者相当。
    The development of laparoscopic liver surgery, the improvement in the perioperative care programs, and the surgical innovation have allowed liver resections on selected cirrhotic patients. However, the great majority of ERAS studies for liver surgery have been conducted on patients with normal liver parenchyma, while its application on cirrhotic patients is limited. The purpose of this study was to evaluate the implementation of an ERAS protocol in cirrhotic patients who underwent liver surgery. We present an analytical observational prospective cohort study, which included all adult patients who underwent a liver resection between December 2017 and December 2019 with an ERAS program. We compare the outcomes in patients cirrhotic (CG)/non-cirrhotic (NCG). A total of 101 patients were included. Thirty of these (29.7%) were patients ≥ 70 cirrhotic. 87% of the both groups had performed > 70% of the ERAS. Oral diet tolerance and mobilization on the first postoperative day were similar in both groups. The hospital stay was similar in both groups (2.9 days/2.99 days). Morbidity and mortality were similar; Clavien I-II (CG: 44% vs NCG: 30%) and Clavien ≥ III (CG: 3% vs NCG: 8%). Hospital re-entry was higher in the NCG. Overall mortality of the study was 1%. ERAS protocol compliance was associated with a decrease in complications (ERAS < 70%: 80% vs ERAS > 90%: 20%; p: 0.02) and decrease in severity of complications in both study groups. The application of the ERAS program in cirrhotic patients who undergo liver surgery is feasible, safe, and reproducible. It allows postoperative complications, mortality, hospital stay, and readmission rates comparable to those in standard patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Multicenter Study
    背景:在过去的几十年中,西方世界肝细胞癌(HCC)的发病率正在增加。由于肝切除术(LR)是最有效的治疗选择之一,解剖(ALR)与非解剖性肝切除术(NALR)的优势显示缺乏一致的证据.因此,这项研究的目的是调查两种切除类型后的并发症和生存率.
    方法:这是一项多中心队列研究,使用回顾性和前瞻性收集的数据。我们纳入了2009年至2020年期间来自瑞士和德国三个专业中心的所有接受LR治疗HCC的患者。使用单和多变量Cox回归模型分析ALR与NALR后的并发症和生存率。
    结果:纳入了二百九十八名患者。中位随访时间为52.76个月。164/298例患者(55%)接受ALR。显著更多的肝硬化患者接受NALR(n=94/134;p<0.001)。根据ClavienDindo分类的并发症在NALR组中明显更常见(p<0.001)。ALR后的肝功能衰竭发生率为13%,NALR后的肝功能衰竭发生率为8%(p<0.215)。单和多变量cox回归模型显示两组之间无复发生存期(RFS)和总生存期(OS)无显著差异。此外,肝硬化对OS和RFS无显著影响。
    结论:可以观察到RFS和OS率没有显着差异。ALR组术后并发症的发生率明显较低,而两组之间的肝脏特异性并发症具有可比性。亚组分析显示,肝硬化对这些患者的术后结局没有显着影响。
    BACKGROUND: The incidence of hepatocellular carcinoma (HCC) is increasing in the western world over the past decades. As liver resection (LR) represents one of the most efficient treatment options, advantages of anatomic (ALR) versus non-anatomic liver resection (NALR) show a lack of consistent evidence. Therefore, the aim of this study was to investigate complications and survival rates after both resection types.
    METHODS: This is a multicentre cohort study using retrospectively and prospectively collected data. We included all patients undergoing LR for HCC between 2009 and 2020 from three specialised centres in Switzerland and Germany. Complication and survival rates after ALR versus NALR were analysed using uni- and multivariate Cox regression models.
    RESULTS: Two hundred and ninety-eight patients were included. Median follow-up time was 52.76 months. 164/298 patients (55%) underwent ALR. Significantly more patients with cirrhosis received NALR (n = 94/134; p < 0.001). Complications according to the Clavien Dindo classification were significantly more frequent in the NALR group (p < 0.001). Liver failure occurred in 13% after ALR versus 8% after NALR (p < 0.215). Uni- and multivariate cox regression models showed no significant differences between the groups for recurrence free survival (RFS) and overall survival (OS). Furthermore, cirrhosis had no significant impact on OS and RFS.
    CONCLUSIONS: No significant differences on RFS and OS rates could be observed. Post-operative complications were significantly less frequent in the ALR group while liver specific complications were comparable between both groups. Subgroup analysis showed no significant influence of cirrhosis on the post-operative outcome of these patients.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    本研究旨在比较不同肿瘤负荷评分(TBS)队列中切除(RES)和微波消融(MWA)的预后结果。
    我们回顾性分析了在我们机构接受RES(n=329)或MWA(n=150)治疗的479例原发性肝细胞癌(HCC)患者。我们使用Kaplan-Meier曲线评估了他们的总生存期(OS)和无进展生存期(PFS)。进行倾向评分匹配(PSM)和治疗加权的逆概率(IPTW)以最小化选择和混杂偏差。多变量Cox回归用于定义手术方式与结果之间的关联。
    在PSM之后,在TBS≤3队列中,累计1-,3-,RES和MWA组中的5年OS分别为92.5%和98.8%,82.7%vs.90.0%,和82.7%vs.83.2%(P=0.366),分别。RES和MWA组相应的PFS率为82.7%。88.0%,63.6%与68.3%和55.2%与分别为56.3(P=0.218)。在TBS>3队列中,累计1-,3-,RES和MWA组之间的5年OS分别为92.5%和95.0%,82.8%与73.2%和76.3%vs.55.1%,(P=0.034),分别。RES和MWA组相应的PFS率为78.0%。67.5%,63.6%与37.5%和55.2%vs.37.1%,分别为(P=0.044)。IPTW分析显示出与PSM分析中所示相似的结果。多变量Cox回归表明,在TBS≤3的队列中,手术方式的类型与较差的预后结果无关。与TBS>3队列不同。
    TBS,作为一个鉴别器,可能有助于指导米兰标准内HCC的治疗决策。
    UNASSIGNED: This study aims to compare the prognostic outcome of resection (RES) and microwave ablation (MWA) in different tumor burden score (TBS) cohorts.
    UNASSIGNED: We retrospectively analyzed 479 patients with primary hepatocellular carcinoma (HCC) who underwent RES (n = 329) or MWA (n = 150) with curative intent at our institution. We assessed their overall survival (OS) and progression-free survival (PFS) using the Kaplan-Meier curve. Propensity score matching (PSM) and inverse probability of treatment weighting (IPTW) were performed to minimize selection and confounding biases. Multivariate Cox regression was used to define the association between surgical modalities and outcomes.
    UNASSIGNED: Following PSM, in the TBS ≤3 cohort, the cumulative 1-, 3-, 5- year OS in the RES and MWA groups were 92.5% vs. 98.8%, 82.7% vs. 90.0%, and 82.7% vs. 83.2% (P = 0.366), respectively. The corresponding PFS rates in the RES and MWA groups were 82.7% vs. 88.0%, 63.6% vs. 68.3% and 55.2% vs. 56.3, respectively (P = 0.218). In the TBS >3 cohort, the cumulative 1-, 3-, 5- year OS between the RES and MWA groups were 92.5% vs. 95.0%, 82.8% vs. 73.2% and 76.3% vs. 55.1%, (P = 0.034), respectively. The corresponding PFS rates in the RES and MWA groups were 78.0% vs. 67.5%, 63.6% vs. 37.5% and 55.2% vs. 37.1%, respectively (P = 0.044). The IPTW analysis showed similar results as shown in PSM analysis. The multivariate Cox regression indicated that the type of surgical modality was not associated with a poorer prognostic outcome in the TBS ≤3 cohort, unlike in the TBS >3 cohort.
    UNASSIGNED: TBS, as a discriminator, might help guide treatment decision-making for HCC within the Milan criteria.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:本研究旨在比较肝切除术(LR)和微波消融(MWA)对早期复发和不同阶段肝硬化的肝细胞癌(HCC)患者的有效性。
    方法:本研究分析了2002年12月至2020年12月在同济医院接受肝切除术并经历早期肿瘤复发(≤3cm)的HCC患者。使用倾向评分匹配(PSM)分析评估治疗有效性。
    结果:这项研究包括295例患者(106,LR;189,MWA),选择两组各86例患者作进一步比较,在PSM之后。PSM之后,LR和MWA的无复发生存率(RFS)和总生存率(OS)相似(分别为p=0.060和p=0.118).然而,LR组治疗相关并发症较多.在中度或重度肝硬化患者中,LR组和MWA组的RFS或OS率无显著差异(分别为p=0.779和p=0.772).在没有肝硬化或轻度肝硬化的患者中,LR显示比MWA更好的RFS和OS率(分别为p=0.024和p=0.047)。多因素分析后PSM确定中度或重度肝硬化和复发间隔≤12个月作为肝癌早期复发患者RFS和OS差的独立预测因子。
    结论:LR比MWA对无肝硬化或轻度肝硬化患者的早期HCC复发更有效。显示改进的RFS和OS速率。在中度或重度肝硬化患者中,两种疗法的OS和RFS在统计学上相等.然而,由于并发症发生率低,MWA可能是首选。
    BACKGROUND: This study aimed to compare the effectiveness of liver resection (LR) and microwave ablation (MWA) in hepatocellular carcinoma (HCC) patients with early recurrence and varying stages of cirrhosis.
    METHODS: This study analyzed patients with HCC who underwent hepatectomy and experienced early tumor recurrence (≤3 cm) between December 2002 and December 2020 at the Tongji Hospital. Treatment effectiveness was assessed using a propensity score matching (PSM) analysis.
    RESULTS: This study included 295 patients (106, LR; 189, MWA), 86 patients in each of the 2 groups were chosen for further comparison, after PSM. After PSM, both LR and MWA demonstrated similar recurrence-free survival (RFS) and overall survival (OS) rates (p = 0.060 and p = 0.118, respectively). However, the LR group had more treatment-related complications. In patients with moderate or severe cirrhosis, no significant differences in RFS or OS rates were found between the LR and MWA groups (p = 0.779 and p = 0.772, respectively). In patients without cirrhosis or with mild cirrhosis, LR showed better RFS and OS rates than MWA (p = 0.024 and p = 0.047, respectively). Multivariate analysis after PSM identified moderate or severe cirrhosis and recurrence intervals ≤12 months as independent predictors of poor RFS and OS in patients with early recurrence of HCC.
    CONCLUSIONS: LR is more effective than MWA for early recurrence of HCC in patients without cirrhosis or with mild cirrhosis, showing improved RFS and OS rates. In patients with moderate or severe cirrhosis, the OS and RFS were statistically equal between the two therapies. However, MWA may be preferred owing to its low complication rate.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:人工智能(AI)作为决策和结果预测工具变得越来越有用。我们已经开发了AI模型来预测7和8段腹腔镜肝脏手术的手术复杂性和术后过程。
    方法:我们从国际多机构数据库中纳入了通过微创肝脏手术进行的第7和第8段病变的患者。我们采用AI模型来预测手术复杂性和术后结果。此外,我们已经应用了Shapley加法扩张(SHAP)来使AI模型可解释。最后,我们分析了未转换为开放的手术与转换为开放的手术。
    结果:总体而言,包括585例患者和22个变量。多层感知器(MLP)在预测手术复杂性方面表现出最高的性能,而随机森林(RF)在预测术后结果方面表现出最高的性能。SHAP检测到MLP和RF对预测手术复杂性和术后结果的变量“切除类型”和“最大肿瘤大小”的相关性最高。此外,我们探索了转换为开放和非转换的手术,发现变量“肿瘤位置”的统计学显著差异,\"\"失血,“\”并发症,\"和\"操作时间。
    结论:我们已经观察到SHAP的应用如何使我们能够了解AI模型对手术复杂性的预测以及腹腔镜肝脏手术第7段和第8段的术后结果。
    BACKGROUND: Artificial intelligence (AI) is becoming more useful as a decision-making and outcomes predictor tool. We have developed AI models to predict surgical complexity and the postoperative course in laparoscopic liver surgery for segments 7 and 8.
    METHODS: We included patients with lesions located in segments 7 and 8 operated by minimally invasive liver surgery from an international multi-institutional database. We have employed AI models to predict surgical complexity and postoperative outcomes. Furthermore, we have applied SHapley Additive exPlanations (SHAP) to make the AI models interpretable. Finally, we analyzed the surgeries not converted to open versus those converted to open.
    RESULTS: Overall, 585 patients and 22 variables were included. Multi-layer Perceptron (MLP) showed the highest performance for predicting surgery complexity and Random Forest (RF) for predicting postoperative outcomes. SHAP detected that MLP and RF gave the highest relevance to the variables \"resection type\" and \"largest tumor size\" for predicting surgery complexity and postoperative outcomes. In addition, we explored between surgeries converted to open and non-converted, finding statistically significant differences in the variables \"tumor location,\" \"blood loss,\" \"complications,\" and \"operation time.\"
    CONCLUSIONS: We have observed how the application of SHAP allows us to understand the predictions of AI models in surgical complexity and the postoperative outcomes of laparoscopic liver surgery in segments 7 and 8.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号